Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 30 May

Bell Direct
May 30, 2024

Morning Bell 29 May

Bell Direct
May 29, 2024

Morning Bell 28 May

Bell Direct
May 28, 2024

Morning Bell 27 May

Grady Wulff
May 27, 2024

Morning Bell 23 May

Bell Direct
May 23, 2024

Morning Bell 22 May

Grady Wulff
May 22, 2024

Morning Bell 21 May

Sam Kanaan
May 21, 2024

Morning Bell 20 May

Grady Wulff
May 20, 2024

Weekly Wrap 17 May

Sophia Mavridis
May 17, 2024

Morning Bell 16 May

Sam Kanaan
May 16, 2024

Weekly Wrap 10 May

Grady Wulff
May 10, 2024